Department of Science Education, National Taipei University of Education, 134, Section 2, Heping E. Road, Da-an District, Taipei 10671, Taiwan.
Evid Based Complement Alternat Med. 2013;2013:287803. doi: 10.1155/2013/287803. Epub 2013 Jan 21.
From fermented Taiwan foods, we have isolated numerous lactic acid bacteria (LAB) of plant origin and investigated their biological activities. This study aimed to investigate the immunomodulatory effect and mechanism of Lactococcus lactis A17 (A17), isolated from Taiwan fermented cabbage, on ovalbumin (OVA)-sensitized mice. Human peripheral blood mononuclear cells were used to verify immune responses of A17 by IFN-γ production. Live (A17-A) and heat-killed A17 (A17-H) were orally administered to OVA-sensitized BALB/c mice to investigate their effects on immunoglobulin (Ig) and cytokine production. The mRNA expression of Toll-like receptors (TLR) and nucleotide binding oligomerization domain (NOD)-like protein receptors in spleen cells was analyzed by real-time RT-PCR. Both live and heat-killed A17 modulate OVA-induced allergic effects. B-cell response was modulated by diminishing IgE production and raising OVA-specific IgG2a production, while T-cell response was modulated by increasing IFN-γ production and decreasing IL-4 production. The mRNA expression of NOD-1, NOD-2, and TLR-4 was down-regulated by A17 as well. This is the first report to describe a naïve Lactococcus lactis A17 strain as a promising candidate for prophylactic and therapeutic treatments of allergic diseases via oral administration. Our results suggest the ameliorative effects of A17 may be caused by modulating NOD-1 NOD-2, and TLR-4 expression.
从台湾发酵食品中,我们分离出了许多植物来源的乳酸菌(LAB),并研究了它们的生物活性。本研究旨在研究从台湾发酵白菜中分离出的乳球菌 lactis A17(A17)对卵清蛋白(OVA)致敏小鼠的免疫调节作用及其机制。使用人外周血单核细胞通过 IFN-γ产生来验证 A17 的免疫反应。将活菌(A17-A)和热灭活 A17(A17-H)口服给予 OVA 致敏的 BALB/c 小鼠,以研究它们对免疫球蛋白(Ig)和细胞因子产生的影响。通过实时 RT-PCR 分析脾细胞中 Toll 样受体(TLR)和核苷酸结合寡聚化结构域(NOD)样蛋白受体的 mRNA 表达。活菌和热灭活 A17 均可调节 OVA 诱导的过敏作用。B 细胞反应通过减少 IgE 产生和增加 OVA 特异性 IgG2a 产生来调节,而 T 细胞反应通过增加 IFN-γ产生和减少 IL-4 产生来调节。A17 还下调了 NOD-1、NOD-2 和 TLR-4 的 mRNA 表达。这是首次描述一种原始的乳球菌 lactis A17 菌株可通过口服给药成为预防和治疗过敏性疾病的有前途的候选物。我们的结果表明,A17 的改善作用可能是通过调节 NOD-1、NOD-2 和 TLR-4 的表达引起的。